EUCTR2010-018878-21-GB进行中（未招募）1 期
A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to raltegravir - Atripla toxicity switch to raltegravir study
St Stephen's AIDS Trust0 个研究点目标入组 40 人开始时间: 2010年6月29日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Male or female aged 18 years or above
- •has a documented HIV-1 infection
- •has signed the Informed Consent Form voluntarily
- •is willing to comply with the protocol requirements
- •has an HIV-plasma viral load at screening <50 copies/mL
- •has a CD4 cell count at Screening >50 cells/mm3
- •has been on a stable ART, with at least 3 licensed agents, one of which being EFV, for at least 12 weeks at Screening, and has been on Atripla for at least 4 weeks at screening; the subject must be willing to stay on treatment until Baseline
- •estimated glomerular filtration rate (by MDRD or CG methods) >50 ml/min.
- •has symptomatic toxicity associated with EFV after at least 12 weeks of therapy
- •if female and of childbearing potential, she is using effective birth control methods (as agreed by the investigator) and is willing to continue practising these birth control methods during the trial and for at least 30 days after the end of the trial (or after last intake of investigational ARVs);
- •Note: Women who are postmenopausal for least 2 years, women with total hysterectomy, and women who have a tubal ligation are considered of non-childbearing potential
- •if a heterosexually active male, he is using effective birth control methods and is willing to continue practising these birth control methods during the trial and until follow-up visit
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •is infected with HIV-2
- •is using any concomitant therapy disallowed as per SPC for the study drugs
- •has a currently active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV Infection 1993) with the following exceptions (must be discussed with the sponsor prior to enrolment):
- •?Stable cutaneous Kaposi’s Sarcoma (no pulmonary or gastrointestinal involvement other than oral lesions) unlikely to require systemic therapy during the trial period
- •?CD4 count less than 200 cells/mm3
- •Note: Primary and secondary prophylaxis for an AIDS defining illness is allowed
- •has acute viral hepatitis including, but not limited to, A, B, or C
- •has chronic hepatitis B and/or C with AST and/or ALT >5 x ULN
- •Note: Subjects co-infected with chronic HBV or HCV can enter the trial if clinically stable and not expected to require treatment during the trial period.
- •has received any investigational drug within 30 days prior to the trial drug administration
- •Prior exposure to raltegravir or investigational integrase inhibitors
- •Any tenofovir or emtricitabine associated resistance mutations
- •No baseline resistance test available
- •Clinically significant allergy or hypersensitivity to any trial medication excipients
- •If female, she is pregnant or breastfeeding
- •screening blood results with any grade 3 / 4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).
- •Clinical or laboratory evidence of significantly decreased hepatic function or decompensation: INR > 1.5 or albumin < 30g/L or bilirubin > 2.5 x ULN
- •Resolution of their CNS toxicity between Screening and Baseline visits
- •Any condition (including drug/alcohol abuse) or laboratory results which, in the investigator’s opinion, interfere with assessments or completion of the trial.
研究者
相似试验
已完成
3 期
A multi-center study of empagliflozin in patients with refractory diabetes mellitus with insulin resistanceInsulin resistance syndrome (type A, type B, type non-A non-B), Lipoatrophic diabetes mellitusJPRN-jRCT2051190029Ogawa Wataru8
招募中
1 期
A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to <18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)Hematopoietic stem cell transplant-associated thrombotic microangiopathy(HSCT- TMA)MedDRA version: 20.0Level: SOCClassification code: 10005329Term: Blood and lymphatic system disorders Class: 3CTIS2023-507850-33-00Alexion Pharmaceuticals Inc.40
进行中（未招募）
1 期
Study of ravulizumab in pediatric participants with HSCT-TMAhematopoietic stem cell transplant-associated thrombotic microangiopathyMedDRA version: 20.0Level: PTClassification code 10043645Term: Thrombotic microangiopathySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2020-000761-16-ITALEXION PHARMACEUTICALS INCORPORATED40
进行中（未招募）
1 期
Study of ravulizumab in pediatric participants with HSCT-TMAhematopoietic stem cell transplant-associated thrombotic microangiopathyMedDRA version: 20.0Level: PTClassification code 10043645Term: Thrombotic microangiopathySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2020-000761-16-FRAlexion Pharmaceuticals, Inc.40
招募中
3 期
Study of Ravulizumab in Pediatric Participants With HSCT-TMAJPRN-jRCT2071200070Yokosawa Jun40